EP4529925A1 — Cortexolone-17-alpha- propionate for treating acneiform eruptions
Assigned to Cassiopea SpA · Expires 2025-04-02 · 1y expired
What this patent protects
The present disclosure provides a method of treating a cutaneous acneiform eruption in a subject in need thereof. The method comprises topically administering to the subject an effective amount of cortexolone-17α-propionate. The acneiform eruption can comprise a papule, a pustule…
USPTO Abstract
The present disclosure provides a method of treating a cutaneous acneiform eruption in a subject in need thereof. The method comprises topically administering to the subject an effective amount of cortexolone-17α-propionate. The acneiform eruption can comprise a papule, a pustule, a nodule, crust, a cyst, or any combination thereof on an affected area of the subject. The effective amount of cortexolone-17α-propionate can be administered in a topical pharmaceutical formulation comprising cortexolone-17α-propionate and one or more pharmaceutically acceptable carriers.
Drugs covered by this patent
- Winlevi (CLASCOTERONE) · Sun Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.